The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | MDS updates from the ASH 2024 meeting
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, outlines some highlights in the field of myelodysplastic syndromes (MDS) from the ASH 2024 meeting. Unfortunately, the meeting was underwhelming regarding updates on the treatment of high-risk (HR) MDS, but some new data was presented in the lower-risk (LR) space. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (Ai-generated)
Yeah, so I wish this was going to be the high-risk MDS conference. I think I would have been really excited to see the aza-tami. We know that the trial press release was negative, but still seeing those data would have been really critical. We’re still waiting on VERONA. So I really think what’s most exciting here is particularly in the low-risk space. So we have, of course, luspatercept, you know, moving indications to frontline...
Yeah, so I wish this was going to be the high-risk MDS conference. I think I would have been really excited to see the aza-tami. We know that the trial press release was negative, but still seeing those data would have been really critical. We’re still waiting on VERONA. So I really think what’s most exciting here is particularly in the low-risk space. So we have, of course, luspatercept, you know, moving indications to frontline. We kind of have fresh off the presses of the imetelstat approval. So how do we sequence? How do we best utilize these therapies? Do we utilize them early before transfusion independence? Do we think about combinations with ESA, with each other? So I think there’s a lot of presentations here looking at optimizing. One, can we start at a higher dose of luspatercept? So start at the 1.75 milligram per kilo. Can we add ESA to luspatercept? We’ve published on this, but there’s some prospective data in that setting. So I think a lot is, you know, how do we further improve our clinical benefit with these therapies is really probably the biggest take home.
I think, you know, we’re going to see some early data and some additional data in the IRAK4 space, both with the Rigel compound and emavusertib from Curis, which has been more high-risk. So I think there’s some interest there. But really, probably optimizing low-risk MDS experiences with elritercept also coming in a pivotal Phase III and some updated data here. I think that’s probably what’s most exciting in MDS, but maybe a little bit underwhelming at this congress than I would have loved.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
